This case study focuses on one aspect of the production, allocation, and distribution of the COVID-19 vaccine: the sharing of intellectual property.
The effort to develop a vaccine for COVID-19 was underway in January 2020, months before the world would experience the full impact of the virus. Hope for a way out of the pandemic focused on rapid development, testing, and deployment of a vaccine, and as it happened, multiple safe and highly effective vaccines were developed in record time. However, ramping up production and determining how to allocate and distribute scarce supplies of vaccines was a major challenge for companies, governments, and societies.
Source link
